Clinical trialNCT00554515CompletedPhase 2Interventional

The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma

SponsorBeth Israel Deaconess Medical CenterEnrollment123Metastatic Renal Cell Carcinoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

High-dose interleukin 2 (Proleukin, Novartis) (IL-2) is approved by the U.S Food and Drug Administration (FDA) for the treatment of metastatic kidney cancer and is a standard treatment of this disease. At the present time, IL-2 is the only therapy for kidney cancer that can produce a remission of disease that lasts after treatment is completed. However, most patients who receive IL-2 do not benefit and all patients experience potentially dangerous side effects. Recent research has suggested that certain patients may respond better to IL-2 than others. The Cytokine Working Group is currently conducting a clinical trial that aims to identify and confirm this research and narrow the application of IL-2 to those patients most likely to benefit.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Allen Pantuck, MD
University of California, Los Angeles
Principal Investigator
clinicaltrials.gov ↗
David F McDermott, MD
Beth Israel Deaconess Medical Center
Study Chair
clinicaltrials.gov ↗
Geoffrey Weiss, MD
University of Virginia
Principal Investigator
clinicaltrials.gov ↗
Janice Dutcher, MD
Our Lady of Mercy Cancer Center
Principal Investigator
clinicaltrials.gov ↗
Jeffrey Sosman, MD
Vanderbilt University
Principal Investigator
clinicaltrials.gov ↗
Joseph Clark, MD
Loyola University
Principal Investigator
clinicaltrials.gov ↗
Kim Margolin, MD
City of Hope National Medical Center
Principal Investigator
clinicaltrials.gov ↗
Leonard Appleman, MD
University of Pittsburgh
Principal Investigator
clinicaltrials.gov ↗
Leslie Oleksowicz, MD
University of Cincinnati
Principal Investigator
clinicaltrials.gov ↗
Marc Ernstoff, MD
Dartmouth-Hitchcock Medical Center
Principal Investigator
clinicaltrials.gov ↗
Michael Wong, MD
Roswell Park Cancer Institute
Principal Investigator
clinicaltrials.gov ↗
Theodore Logan, MD
Indiana University
Principal Investigator
clinicaltrials.gov ↗
Ulka Vaishampayan, MD
Wayne State University
Principal Investigator
clinicaltrials.gov ↗
Walter Urba, MD
Chiles Cancer Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

HD IL2

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Nov 2006
Primary completion: 31 Oct 2013
Completion: 31 Oct 2013
Last update posted: 28 Aug 2024
Registered enrollment: 123
Registry id: NCT00554515

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.